{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:39:14Z","timestamp":1789555154537,"version":"build-2803163510"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA264563"],"award-info":[{"award-number":["R37CA264563"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Industry payments to physician\u2019s influence prescribing, raising concern for drugs granted accelerated approval that failed confirmatory studies. We measured industry payments for oncology drugs granted accelerated approval before and after negative confirmatory study results. From 2009 to 2021, of 73 drugs granted accelerated approval, 6 (8.2%) had negative confirmatory studies and available OpenPayments data. These were withdrawn a median of 0.3 (interquartile range = 0.3-0.6) years after announcement of negative results. Two drugs had almost no payments after negative result announcement. Among other 4, average monthly payments in the year preceding announcement of negative results to the period between results and market withdrawal went from $138 to $183 for vinCRIStine sulfate, $12\u2009317 to $4606 for Panobinostat, $152\u2009417 to $119\u2009066 for belantamab mafodotin, and $23\u2009139 to $13\u2009588 for umbralisib. Whereas payments for oncology drugs with accelerated approvals mostly decreased, industry promotion continued for certain drugs after confirmatory studies failed until drugs were withdrawn from market.<\/jats:p>","DOI":"10.1093\/jnci\/djaf241","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T11:49:23Z","timestamp":1755690563000},"page":"936-940","source":"Crossref","is-referenced-by-count":2,"title":["Industry promotion of oncology drugs with accelerated approval that failed confirmatory trials"],"prefix":"10.1093","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9347-494X","authenticated-orcid":false,"given":"Maryam","family":"Mooghali","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Yale School of Medicine , New Haven, CT,","place":["United States"]},{"name":"Yale Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT), Yale School of Medicine , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3845-3606","authenticated-orcid":false,"given":"Reshma","family":"Ramachandran","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale School of Medicine , New Haven, CT,","place":["United States"]},{"name":"Yale Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT), Yale School of Medicine , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8837-0859","authenticated-orcid":false,"given":"Ayman","family":"Mohammad","sequence":"additional","affiliation":[{"name":"Department of Medicine, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3639-3515","authenticated-orcid":false,"given":"Aaron P","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"2026050811432374800_djaf241-B1","author":"U.S. Food and Drug Administration","year":"2025"},{"key":"2026050811432374800_djaf241-B2","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s43441-022-00430-z","article-title":"Analysis of FDA's accelerated approval program performance December 1992-December 2021","volume":"56","author":"Beakes-Read","year":"2022","journal-title":"Ther Innov Regul Sci"},{"key":"2026050811432374800_djaf241-B3","doi-asserted-by":"publisher","first-page":"100364","DOI":"10.1016\/j.jcpo.2022.100364","article-title":"FDA validation of surrogate endpoints in oncology: 2005-2022","volume":"34","author":"Walia","year":"2022","journal-title":"J Cancer Policy"},{"key":"2026050811432374800_djaf241-B4","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jama.2024.2396","article-title":"Clinical benefit and regulatory outcomes of cancer drugs receiving accelerated approval","volume":"331","author":"Liu","year":"2024","journal-title":"JAMA"},{"key":"2026050811432374800_djaf241-B5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s12032-024-02563-7","article-title":"The physician payments Sunshine Act and medical oncology: a seven-year financial analysis","volume":"42","author":"Zhao","year":"2024","journal-title":"Med Oncol"},{"key":"2026050811432374800_djaf241-B6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.7326\/m20-5665","article-title":"Are financial payments from the pharmaceutical industry associated with physician prescribing?: a systematic review","volume":"174","author":"Mitchell","year":"2021","journal-title":"Ann Intern Med"},{"key":"2026050811432374800_djaf241-B7","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1634\/theoncologist.2018-0423","article-title":"Evaluating the strength of the association between industry payments and prescribing practices in oncology","volume":"24","author":"Mitchell","year":"2019","journal-title":"Oncologist"},{"key":"2026050811432374800_djaf241-B8","doi-asserted-by":"publisher","first-page":"i4189","DOI":"10.1136\/bmj.i4189","article-title":"Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study","volume":"354","author":"Fleischman","year":"2016","journal-title":"BMJ"},{"key":"2026050811432374800_djaf241-B9","doi-asserted-by":"publisher","first-page":"e2022056549","DOI":"10.1542\/peds.2022-056549","article-title":"Health care clinicians and product promotion by industry","volume":"149","author":"Diekema","year":"2022","journal-title":"Pediatrics"},{"key":"2026050811432374800_djaf241-B10","doi-asserted-by":"publisher","first-page":"e000802","DOI":"10.1136\/bmjmed-2023-000802","article-title":"Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional study","volume":"3","author":"Mooghali","year":"2024","journal-title":"BMJ Med"},{"key":"2026050811432374800_djaf241-B11","doi-asserted-by":"publisher","first-page":"104402","DOI":"10.1016\/j.jpubeco.2021.104402","article-title":"Drug firms\u2019 payments and physicians\u2019 prescribing behavior in Medicare Part D","volume":"197","author":"Carey","year":"2021","journal-title":"J Public Econ"},{"key":"2026050811432374800_djaf241-B12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41408-025-01212-0","article-title":"The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development","volume":"15","author":"Mukhopadhyay","year":"2025","journal-title":"Blood Cancer J"},{"key":"2026050811432374800_djaf241-B13","doi-asserted-by":"publisher","first-page":"e075512","DOI":"10.1136\/bmj-2023-075512","article-title":"Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study","volume":"383","author":"Mitchell","year":"2023","journal-title":"BMJ"},{"key":"2026050811432374800_djaf241-B14","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1093\/jnci\/djab192","article-title":"Annual report to the nation on the status of cancer, part 2: patient economic burden associated with cancer care","volume":"113","author":"Yabroff","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2026050811432374800_djaf241-B15","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1001\/jamainternmed.2021.5989","article-title":"Estimated medicare spending on cancer drug indications with a confirmed lack of clinical benefit after US food and drug administration accelerated approval","volume":"181","author":"Shahzad","year":"2021","journal-title":"JAMA Int Med"},{"key":"2026050811432374800_djaf241-B16","doi-asserted-by":"publisher","first-page":"e2133601","DOI":"10.1001\/jamanetworkopen.2021.33601","article-title":"Comparison of duration of postapproval vs pivotal trials for therapeutic agents granted US Food and Drug Administration Accelerated Approval, 2009-2018","volume":"4","author":"Wallach","year":"2021","journal-title":"JAMA Netw Open"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djaf241\/64129065\/djaf241.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/5\/936\/64129065\/djaf241.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/5\/936\/64129065\/djaf241.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:43:27Z","timestamp":1778255007000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/118\/5\/936\/8241020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":16,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,8,26]]},"published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djaf241","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,8,26]]}}}